Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.

Leukemia · 2021 · PMC8179841 · PMID 32895455

Europe PMC DOI

hedged sentence

0.1927

closest p · 3.9× alpha

0.1927

boldest claim

The sentences

did not reach statistical significanceP = 0.1927not close (p > 0.1)

Additionally, among patients who were previously treated with RVd, median PFS was longer with PVd vs Vd (14.7 vs 11.6 months), although the difference for this post hoc comparison did not reach statistical significance ( P = 0.1927).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.